Cargando…

Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population

BACKGROUND: Despite the favorable prognosis for medullary breast cancer (MBC), the guidelines for the use of adjuvant chemotherapy for MBC have not been clearly established. This study investigated the prognostic role of adjuvant chemotherapy in Korean patients with node-negative (N0), triple-negati...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, SeungTaek, Park, Se Ho, Park, Heong Kyu, Hur, Min Hee, Oh, Se Jeong, Suh, Young Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642937/
https://www.ncbi.nlm.nih.gov/pubmed/26562837
http://dx.doi.org/10.1371/journal.pone.0140208
_version_ 1782400436268957696
author Lim, SeungTaek
Park, Se Ho
Park, Heong Kyu
Hur, Min Hee
Oh, Se Jeong
Suh, Young Jin
author_facet Lim, SeungTaek
Park, Se Ho
Park, Heong Kyu
Hur, Min Hee
Oh, Se Jeong
Suh, Young Jin
author_sort Lim, SeungTaek
collection PubMed
description BACKGROUND: Despite the favorable prognosis for medullary breast cancer (MBC), the guidelines for the use of adjuvant chemotherapy for MBC have not been clearly established. This study investigated the prognostic role of adjuvant chemotherapy in Korean patients with node-negative (N0), triple-negative (TN) MBC patients. METHODS: We included data from 252 patients with N0 TN MBC, obtained from the Korean Breast Cancer Registry database. Patients were categorized as those who did not undergo adjuvant chemotherapy (group I) or those who did (group II). Clinicopathological characteristics, breast cancer-specific survival (BCSS), and overall survival (OS) were compared between the groups. In addition, a subgroup analysis for survival based on tumor size was conducted. RESULTS: A total of 252 N0 TN MBC patients with tumor sizes >1 cm who were diagnosed between April 1997 and March 2011 were enrolled. The median age was 44.95 years (range, 25–72 years), and the median follow-up period was 93.94 months (range, 23–195 months). Overall, the BCSS and OS in group II (97.3% and 97.3%, respectively) were significantly better compared with those in group I (89.2% and 86.2%, respectively). In the subgroup analysis, in patients with tumors >2 cm in size, those in group II had significant better BCSS and OS (97.5% and 97.5%, respectively) compared with those in group I (78.3% and 73.9%, respectively). In contrast in those with tumors 1–2 cm in size, there were no significant differences in BCSS and OS between the groups (both 97.1% for group I, and 95.2% and 92.9%, respectively for group II). Multivariate analysis revealed that adjuvant chemotherapy significantly improved BCSS (P = 0.009) and OS (P = 0.007), but only for patients with larger tumors (>2 cm). CONCLUSIONS: In patients with N0 TN MBC, adjuvant chemotherapy had a significant clinical survival benefit, but only in those with tumors >2 cm.
format Online
Article
Text
id pubmed-4642937
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-46429372015-11-18 Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population Lim, SeungTaek Park, Se Ho Park, Heong Kyu Hur, Min Hee Oh, Se Jeong Suh, Young Jin PLoS One Research Article BACKGROUND: Despite the favorable prognosis for medullary breast cancer (MBC), the guidelines for the use of adjuvant chemotherapy for MBC have not been clearly established. This study investigated the prognostic role of adjuvant chemotherapy in Korean patients with node-negative (N0), triple-negative (TN) MBC patients. METHODS: We included data from 252 patients with N0 TN MBC, obtained from the Korean Breast Cancer Registry database. Patients were categorized as those who did not undergo adjuvant chemotherapy (group I) or those who did (group II). Clinicopathological characteristics, breast cancer-specific survival (BCSS), and overall survival (OS) were compared between the groups. In addition, a subgroup analysis for survival based on tumor size was conducted. RESULTS: A total of 252 N0 TN MBC patients with tumor sizes >1 cm who were diagnosed between April 1997 and March 2011 were enrolled. The median age was 44.95 years (range, 25–72 years), and the median follow-up period was 93.94 months (range, 23–195 months). Overall, the BCSS and OS in group II (97.3% and 97.3%, respectively) were significantly better compared with those in group I (89.2% and 86.2%, respectively). In the subgroup analysis, in patients with tumors >2 cm in size, those in group II had significant better BCSS and OS (97.5% and 97.5%, respectively) compared with those in group I (78.3% and 73.9%, respectively). In contrast in those with tumors 1–2 cm in size, there were no significant differences in BCSS and OS between the groups (both 97.1% for group I, and 95.2% and 92.9%, respectively for group II). Multivariate analysis revealed that adjuvant chemotherapy significantly improved BCSS (P = 0.009) and OS (P = 0.007), but only for patients with larger tumors (>2 cm). CONCLUSIONS: In patients with N0 TN MBC, adjuvant chemotherapy had a significant clinical survival benefit, but only in those with tumors >2 cm. Public Library of Science 2015-11-12 /pmc/articles/PMC4642937/ /pubmed/26562837 http://dx.doi.org/10.1371/journal.pone.0140208 Text en © 2015 Lim et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Lim, SeungTaek
Park, Se Ho
Park, Heong Kyu
Hur, Min Hee
Oh, Se Jeong
Suh, Young Jin
Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population
title Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population
title_full Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population
title_fullStr Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population
title_full_unstemmed Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population
title_short Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population
title_sort prognostic role of adjuvant chemotherapy in node-negative (n0), triple-negative (tn), medullary breast cancer (mbc) in the korean population
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642937/
https://www.ncbi.nlm.nih.gov/pubmed/26562837
http://dx.doi.org/10.1371/journal.pone.0140208
work_keys_str_mv AT limseungtaek prognosticroleofadjuvantchemotherapyinnodenegativen0triplenegativetnmedullarybreastcancermbcinthekoreanpopulation
AT parkseho prognosticroleofadjuvantchemotherapyinnodenegativen0triplenegativetnmedullarybreastcancermbcinthekoreanpopulation
AT parkheongkyu prognosticroleofadjuvantchemotherapyinnodenegativen0triplenegativetnmedullarybreastcancermbcinthekoreanpopulation
AT hurminhee prognosticroleofadjuvantchemotherapyinnodenegativen0triplenegativetnmedullarybreastcancermbcinthekoreanpopulation
AT ohsejeong prognosticroleofadjuvantchemotherapyinnodenegativen0triplenegativetnmedullarybreastcancermbcinthekoreanpopulation
AT suhyoungjin prognosticroleofadjuvantchemotherapyinnodenegativen0triplenegativetnmedullarybreastcancermbcinthekoreanpopulation